Shots:
- Adlai Nortye has granted ASK Pharm exclusive rights to develop, manufacture, & commercialize AN9025 in mainland China, Hong Kong & Macao, with Adlai retaining rights in other regions
- As per the deal, Adlai will receive ~$230M, incl. >$20M in upfront & near-term milestone, plus tiered royalties ranging from a high single-digit to mid-teens % of net product sales in the ASK’s licensed areas
- AN9025 is an oral pan-RAS(ON) inhibitor targeting multiple RAS mutations, with preclinical data showing durable activity across pancreatic, lung & colorectal cancers, & a P-I study planned for Q1’26
Ref: Globenewswire | Image: Adlai Nortye & ASK Pharm | Press Release
Related News: Adagene Enters ~$845M Licensing Deal with Third Arc Bio to Develop Masked CD3 T Cell Engagers
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
